32428 Secukinumab is effective and safe in the treatment of recalcitrant palmar-plantar psoriasis and palmar-plantar pustular psoriasis in a daily practice setting

Abstract

Background: Palmar-plantar psoriasis (PP) and palmar-plantar pustular psoriasis (PPPP) are frequently recalcitrant to treatment. Currently we have limited information from guidelines for their management. Objective: To study drug effectiveness, safety and persistence as well as quality of life in patients with PP and PPPP treated with secukinumab (SEK) in real clinical practice. Methods: Retrospective, observational, noncontrolled, multicenter cohort, long-term study of patients with moderate-to-severe PP and PPPP (ppIGA/pppIGA score of ≥3) treated with SEK under daily practice conditions, conducted between January 2014 and July 2020. Results: Seventy-two patients (55 PP, 17 PPPP) were included. A 56.36% and 52.94% of PP and PPPP patients, respectively, achieved ppIGA/pppIGA response scores of 0 or 1 or a reduction of at least 2 points on the ppIGA/pppIGA scale from baseline in the 24-month follow-up. We found statistically significant differences in the ppIGA at 12 months between naïve subjects and patients with prior biologic therapy, with greater effectiveness in naïve patients. The mean drug survival for PP and PPP patients were 12.7 and 13.4 months, respectively. Safety profile was good. Limitations: Those derived from the retrospective and multicenter nature of the study with patients treated in daily clinical practice. Conclusions and relevance: SEK is a safe, fast and effective treatment alternative for some patients with PP and PPPP refractory to previous systemic or biologic treatments.